Targets › S1PR5
3 programs from 3 companies in 14 trials: 6 Phase 2, 4 Phase 4, 3 Phase 3, 1 Phase 1; Neurology, Immunology, Gastroenterology; next expected readout Sep 2027.
Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. (UniProt, Q9H228)
Open in Phaseline: the race on S1PR5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Fingolimod Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | S1PR5, S1PR2, S1PR4, S1PR3, S1PR1 | Phase 4 | Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung Cancer | Sep 2027 |
| Bristol-Myers Squibb | Ozanimod Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor 5 modulator | S1PR1, S1PR5 | Phase 4 | Relapsing Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Colitis, Ulcerative; Alzheimer Disease | Dec 2028 |
| Pfizer | Etrasimod Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator | S1PR1, S1PR4, S1PR5 | Phase 3 | Ulcerative Colitis; Colitis, Ulcerative; Healthy Participant; Pouchitis | Jun 2029 |
Relapsing Multiple Sclerosis (2) Colitis, Ulcerative (2) Ulcerative Colitis (2) Multiple Sclerosis (2) Multiple Sclerosis, Relapsing-Remitting (1) Alzheimer Disease (1) Healthy Participant (1) Pouchitis (1) Diabetes Mellitus, Type 2 (1) Non Small Cell Lung Cancer (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.